Upgrade to SI Premium - Free Trial

Benchmark Reiterates Buy Rating on Abbott Labs (ABT) Ahead of Q2 Results

July 15, 2026 9:24 AM
Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $120.00 price target on Abbott Labs (NYSE: ABT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments